Analytical Data
-
基因名
APRIL/TNFSF13 Trimer
- Application
-
别名
CD256; APRIL; TALL2; TRDL1; ZTNF2; A Proliferation Inducing Ligand; TNF And APOL Related Leukocyte Expressed Ligand 2; TNF-Related Death Ligand 1
-
种属
Rat
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 85% as determined by SDS-PAGE.
-
蛋白编号
NM_001009623.1
-
表达区间
Ala96~Leu240
-
分子量
20kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
APRIL (A Proliferation-Inducing Ligand) and TNFSF13 (Tumor Necrosis Factor Superfamily Member 13) are key cytokines involved in the regulation of immune responses and B cell survival. APRIL functions as a trimeric protein that binds to its receptors, BAFF-R and TACI, influencing the proliferation, differentiation, and survival of B cells in the immune system. Due to its significant role in promoting B cell maturation and class switching, abnormalities in APRIL signaling are linked to various autoimmune diseases and malignancies. Research into recombinant forms of APRIL/TNFSF13 trimer proteins has gained traction as a potential therapeutic strategy, allowing for the detailed study of their mechanisms and effects on immune modulation. The availability of recombinant APRIL/TNFSF13 trims provides valuable tools for understanding the pathological processes involved in diseases characterized by dysregulated B cell activity. Furthermore, the trimeric structure is crucial for functional activity, as it enhances receptor binding and signaling efficacy. Through the investigation of this recombinant protein, researchers aim to uncover novel insights into the therapeutic targeting of B cell-related disorders and to develop innovative strategies for modulating immune responses in clinical settings. Overall, the study of APRIL/TNFSF13 trimer is at the forefront of immunological research, reflecting its potential applications in treating autoimmune diseases, lymphomas, and other immune-related conditions.
